Allergan’s Botox Gains Continue, Pipeline Progresses Ahead Of AbbVie Merger
Key Allergan drugs performed well in Q3 and pipeline programs are approaching milestones as AbbVie says its $63bn acquisition of the company remains on track to close early next year.
You may also be interested in...
With adalimumab biosimilars now on market in the US, AbbVie said it expects sales erosion this year toward the lower end of its previous guidance, with pricing comprising the larger portion of the hit.
Despite Humira’s ex-US sales erosion, AbbVie reports strong launches for Skyrizi and Rinvoq, continued growth for hematological oncology franchise, and boasts it has a thriving R&D engine.
The only addition to AbbVie’s leadership after it closes the $63bn acquisition of Allergan will be Carrie Strom, who will lead the Allergan Aesthetics business.